APR 08, 2017 10:19 AM PDT

Is Diabetes Reversal Within Reach?

WRITTEN BY: Xuan Pham

While treatments for diabetes management have gotten better over the year, wouldn’t it be best if we could reverse the disease altogether? The first promise of such a drug was announced recently, with a compound that seemingly normalized insulin signaling in mice.

Currently, type 2 diabetes affects more than 29 million Americans alone. And this number is predicted to increase globally. For patients with diabetes, managing their blood sugar levels requires constant care and vigilance. For the healthcare system, diabetes represents a significant financial burden. The American Diabetes Association estimates that for every $3 Medicare dollars, $1 is spent caring for people with diabetes. The burden of diabetes and pre-diabetes treatment cost America $322 billion every year.

So, it’s not just a matter of making diabetes more manageable. The most cost-efficient solution is to either prevent or reverse diabetes.

Towards that end, researchers at the UC San Diego School of Medicine focused on a drug that could restore the body’s insulin sensitivity. The pill they came up with inhibits an enzyme known as low molecular weight protein tyrosine phosphatase (LMPTP). “We found that LMPTP is a critical promoter of insulin resistance that develops during obesity,” said Stephanie Stanford, the study’s lead author.

Stopping the enzyme in the liver seemed to stop animals from developing diabetes even when exposed to a high-fat diet. “Our inhibitor increased activation of the insulin receptor in the liver, and reversed diabetes without any apparent negative side effects,” says Stanford. The liver is the organ that mainly absorbs excess sugar from the blood in the presence of insulin.

“This could lead to a new therapeutic strategy for treating type 2 diabetes,” said Stanford. If this new drug works in humans, it could be used to reverse insulin resistance, and reduce the number of people dependent on insulin shots. Thus, the next hurdle for this proof-of-concept study is a clinical trial to observe the drug’s effects in patients.

“Our compound is very specific for the target, and we do not see any side effects after treatment in mice for a month, but the next step is to rigorously establish if it’s safe for use in clinical trials,” said Stanford.

Additional source: New Scientist

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
FEB 26, 2020
Clinical & Molecular DX
Is your kid's stomach ache from appendicitis? Probably not.
FEB 26, 2020
Is your kid's stomach ache from appendicitis? Probably not.
Complaints about a painful belly are a common childhood lament. In such situations, the first thing that often comes to ...
FEB 21, 2020
Clinical & Molecular DX
Diagnosing COVID-19
FEB 21, 2020
Diagnosing COVID-19
Diagnosing coronavirus is done through next-generation sequencing, real-time RT-PCR tests, cell culture, and electron mi ...
APR 13, 2020
Cancer
The Unexpected Role of Mono in Cancer Progression
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 29, 2020
Clinical & Molecular DX
Saliva is Preferable to Deep Nasal Swabs for COVID-19 Testing
APR 29, 2020
Saliva is Preferable to Deep Nasal Swabs for COVID-19 Testing
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Incre ...
MAY 21, 2020
Clinical & Molecular DX
Fidget Spinner Diagnoses Infections
MAY 21, 2020
Fidget Spinner Diagnoses Infections
The fidget spinner toy craze took the world by storm — a small, boomerang-shaped gadget that rotates hypnotically ...
MAY 23, 2020
Microbiology
The FDA Yanks Some COVID-19 Antibody Tests From the Market
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
Loading Comments...